Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Head and Neck Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1502391

PMAIP1 regulates the progression of follicular thyroid carcinoma through the Wnt3/FOSL1 pathway

Provisionally accepted
Haobo Wang Haobo Wang 1*Fangjian Shang Fangjian Shang 1Yifang Wang Yifang Wang 1*Bo Pang Bo Pang 1,2Longfei Kang Longfei Kang 1,2*Chuanmin Zhou Chuanmin Zhou 1,2*Dongyun Li Dongyun Li 1,2*Zhongxin Li Zhongxin Li 1,2*Xia Jiang Xia Jiang 1,2*Bo Liu Bo Liu 1*Zengren Zhao Zengren Zhao 1*
  • 1 Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
  • 2 Gastrointestinal Disease Diagnosis and Treatment Center, Hebei Key Laboratory of Colorectal Cancer Precision Diagnosis and Treatment, The First Hospital of Hebei Medical University, Shijiazhuang, China

The final, formatted version of the article will be published soon.

    In thyroid carcinoma (TC), follicular thyroid carcinoma (FTC) represents the second most prevalent pathological type following papillary thyroid carcinoma. Notably, FTC exhibits a more aggressive clinical course and a higher propensity for distant metastasis. However, the underlying mechanisms governing the progression of FTC remain poorly understood. PMAIP1 is a gene implicated in various cancers and biological processes. Investigating the role and mechanism of PMAIP1 in FTC is crucial for enhancing our understanding of FTC and informing clinical treatment strategies. This study examined the expression level of PMAIP1 in FTC through comprehensive analyses of databases, tumor tissues, and cell lines. Following the establishment of a stably transfected plasmid in cell lines, a series of functional assays and subcutaneous xenograft experiment were conducted to investigate the role of PMAIP1 in FTC. Additionally, transcriptome sequencing was employed to identify potential signaling pathways associated with PMAIP1. Mechanistic studies involved a series of rescue experiments to elucidate the regulatory mechanisms of PMAIP1 in FTC. PMAIP1 was found to be highly expressed in FTC, and its knockdown significantly inhibited the proliferation and metastasis of FTC cells both in vivo and in vitro. The results of transcriptome sequencing analysis indicated that PMAIP1 may influence the progression of FTC via the Wnt signaling pathway. Subsequent investigations revealed a direct correlation between PMAIP1 expression levels and those of Wnt3 and FOSL1 in FTC. A series of rescue experiments further substantiated the regulatory role of PMAIP1 on Wnt3/FOSL1 in FTC.In conclusion, our research demonstrated that PMAIP1 emerges as a novel pro-cancer factor in FTC, and its knockdown significantly inhibited the proliferation and metastasis of FTC both in vivo and in vitro. Mechanistically, PMAIP1 regulated FOSL1 by modulating the Wnt signaling pathway, thereby promoting FTC progression. Targeting PMAIP1 may present a promising therapeutic strategy for FTC.

    Keywords: Follicular thyroid carcinoma, PMAIP1, Wnt3, FOSL1, Progression 1

    Received: 26 Sep 2024; Accepted: 08 Jan 2025.

    Copyright: © 2025 Wang, Shang, Wang, Pang, Kang, Zhou, Li, Li, Jiang, Liu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Haobo Wang, Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
    Yifang Wang, Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
    Longfei Kang, Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
    Chuanmin Zhou, Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
    Dongyun Li, Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
    Zhongxin Li, Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
    Xia Jiang, Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
    Bo Liu, Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China
    Zengren Zhao, Department of General Surgery, The First Hospital of Hebei Medical University, Shijiazhuang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.